1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

Resilience, ‘Lessons Learned’ Must Be COVID Legacy In Germany

 
• By Ashley Yeo

COVID-19 threat is abating and control measures easing, but government commitments made at height of pandemic to forearm against future health care emergencies should not be abandoned, says German Advisory Council on Health and Care and the IVD industry.

• Source: Shutterstock

Another COVID-19 milestone was reached on 28 February when policymakers in Germany – a country often praised for taking early and decisive coronavirus control measures ̶ dropped the need for asymptomatic testing of individuals suspected of SARS-CoV-2 infection.

In the US on the same day, President Biden declared that the state of public health emergency put in place...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By David Ridley

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA Extracts More Evidence To Ban Kratom

 
• By Malcolm Spicer

Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.

More from Policy & Regulation

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 
• By Malcolm Spicer

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA Extracts More Evidence To Ban Kratom

 
• By Malcolm Spicer

Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.